Daklinza(daclatasvir)
Daklinza (daclatasvir) is a small molecule pharmaceutical. Daclatasvir was first approved as Daklinza on 2014-08-22. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daclatasvir dihydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DAKLINZA | Bristol Myers Squibb | N-206843 DISCN | 2015-07-24 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis c | — | D006526 | B19.2 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
211 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 18 | 35 | 37 | 11 | 46 | 141 |
| Hepatitis | D006505 | — | K75.9 | 2 | 22 | 22 | 3 | 29 | 73 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 5 | 19 | 16 | 4 | 28 | 65 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 2 | 12 | 14 | 2 | 25 | 52 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 8 | 5 | 1 | 1 | 13 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 1 | 1 | 7 | 11 |
| Fibrosis | D005355 | — | — | — | 2 | 1 | 1 | 6 | 10 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 6 | 5 | 1 | 1 | 10 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | 1 | 2 | — | 4 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | 1 | 1 | 3 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis | D006521 | — | K73.9 | 1 | 7 | 2 | — | 10 | 18 |
| Hepacivirus | D016174 | — | — | — | 6 | 5 | — | — | 11 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 2 | 1 | — | 3 | 7 |
| Hepatitis b | D006509 | — | — | — | 2 | 3 | — | 2 | 7 |
| Infections | D007239 | EFO_0000544 | — | 1 | 5 | 1 | — | — | 7 |
| Hiv | D006678 | — | O98.7 | 1 | — | 1 | — | 1 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | 1 | — | 1 | 3 |
| Directly observed therapy | D023801 | — | — | — | 1 | 1 | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 3 |
| Coinfection | D060085 | — | — | — | 1 | — | — | 1 | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 5 | 8 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
| Camurati-engelmann syndrome | D003966 | Orphanet_1328 | Q78.3 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Virus diseases | D014777 | — | B34 | — | — | — | — | 2 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 2 | 2 |
| Hemoglobinopathies | D006453 | — | D58.2 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Retinal diseases | D012164 | — | H35.9 | — | — | — | — | 1 | 1 |
| Joint diseases | D007592 | — | M12.9 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 1 | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Daclatasvir |
| INN | daclatasvir |
| Description | Daclatasvir is a member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C. It has a role as a nonstructural protein 5A inhibitor and an antiviral drug. It is a member of biphenyls, a member of imidazoles, a carbamate ester, a carboxamide and a valine derivative. It is a conjugate base of a daclatasvir(2+). |
| Classification | Small molecule |
| Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 1009119-64-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2023898 |
| ChEBI ID | 82977 |
| PubChem CID | 25154714 |
| DrugBank | DB09102 |
| UNII ID | LI2427F9CI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Daklinza – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,698 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,803 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use